Rekod bukti kaedah

Bioequivalence Analysis

Bioequivalence Analysis is a regulatory-grade statistical framework used to determine whether a test drug formulation (generic or reformulated) delivers the active ingredient to the systemic circulation at a rate and extent comparable to a reference product. Introduced by Donald J. Schuirmann in 1987, the method operationalizes equivalence through the Two One-Sided Tests (TOST) procedure, replacing the ambiguous absence-of-difference paradigm with an explicit equivalence margin evaluated on log-transformed pharmacokinetic endpoints such as AUC and C_max.

Sources recorded, not reviewed

Rekod sumber

Petikan disalin secara verbatim daripada rekod sumber kaedah. Tiada pengesahan peringkat tuntutan disimpulkan daripadanya.

Bioequivalence Analysis (Two One-Sided Tests)

Rekod kaedah taksonomik · hypothesis-test / pharmacometrics

Schuirmann, D. J. (1987). A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics, 15(6), 657–680. · DOI 10.1007/BF01068419

Buka kaedah penuh

Tuntutan yang dikurasi

Tuntutan disimpan dalam lejar bukti, setiap satu dengan penilaiannya sendiri.

Tiada tuntutan terkurasi lagi

Pandangan ini tidak mencipta penilaian tuntutan apabila lejar tiada.

Kaedah berkaitan

Dijana daripada graf kaedah dan ditunjukkan sebagai perhubungan yang dicadangkan mesin — tiada tuntutan bukti disimpulkan.

Same method familyEquivalence Test (TOST)machine-suggested · Relational suggestion, not evidence.Used in the same domainPharmacokinetic Compartment Modelmachine-suggested · Relational suggestion, not evidence.